NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aclaris Therapeutics, Inc. (ACRS) Stock Analysis

Aclaris Therapeutics, Inc. (ACRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACRS

$3.81

+$0.04 (+1.06%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACRS with… →

ACRS Key Statistics

As of Oct 21, 2026
Trading
Open
$3.74
Previous Close
$3.77
Day's Range
3.69–3.97
52-Week Range
2.10–6.60
Volume
2.66M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$560.83M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
68.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.58
Financials (FY)
Revenue (FY)
$7.83M−58.19%
Net Income (FY)
−$64.92M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
147.20M
1-Year Return
+60.08%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.74M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACRS closed at $3.81, +60.08% over 1 year.

Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $560.83M.

In fiscal 2025, ACRS reported revenue of $7.83M.

ACRS Stock Return by Calendar Year

Aclaris Therapeutics, Inc. (ACRS) 10-year return: what $10,000 became

1 year
$10,000 $16,008
+60.08%
5 years
$10,000 $2,368
−76.32%
10 years
$10,000 $1,709
−82.91%

If you had invested $10,000 in Aclaris Therapeutics, Inc. (ACRS) 10 years ago, at the close on October 21, 2016, it would have been worth $1,709 at the close on October 21, 2026: −82.91% in total, −16.19% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.58%
2025+21.37%
2024+136.19%
2023−93.33%
2022+8.32%
2021+124.73%
2020+242.33%
2019−74.42%
2018−70.03%
2017−9.14%
2016 (partial year)+44.67%

As of October 21, 2026.

ACRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.83M−$64.92M−829.6%
2024$18.72M−$132.07M−705.5%
2023$31.25M−$88.48M−283.1%
2022$29.75M−$86.91M−292.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.83M$542.00K−$74.08M−$64.92M−829.6%
2024$18.72M$3.26M−$52.53M−$132.07M−705.5%
2023$31.25M$13.17M−$116.31M−$88.48M−283.1%
2022$29.75M$17.79M−$85.15M−$86.91M−292.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACRS Valuation vs Biotechnology Median

Median of 608 stocks
MetricACRSBiotechnology medianvs median
P/S ratio68.2413.305.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aclaris Therapeutics, Inc. (ACRS) at $560.83M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 69.

Over the past 52 weeks the price has ranged from $2.10 to $6.60. The most recent close on file for ACRS is $3.81, dated October 21, 2026. That is +$0.04 (+1.06%) against the previous close. The latest close sits 81.86% above that 52-week low.

Financial Health

In fiscal 2025, Aclaris Therapeutics, Inc. reported revenue of $7.83M. Against the prior fiscal year total of $18.72M, that is a change of −58.19%. The same year closed with a net loss of $64.92M. Earnings per share on a trailing basis come to −0.58.

Across the 4 fiscal years on file, revenue moves from $29.75M in 2022 to $7.83M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 68.24 times revenue. On price-to-sales that is 5.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.88. Daily returns over the trailing 10 years annualize to a volatility of 110.93%. The trailing one-year total return is +60.08%. Across 10 years the annualized return works out at −16.19%.

Growth & Income

The record shows no dividend for ACRS.

The strongest complete calendar year on file is 2020 at +242.33%; the weakest is 2023 at −93.33%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +26.58% year to date.

Peer Comparison

Aclaris Therapeutics, Inc. (ACRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aclaris Therapeutics, Inc. ACRS $560.83M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aclaris Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Visit website →